Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03125629 · ClinicalTrials.gov registry record · Phase 2
Comparison of PET/CT vs. PET/MRI Using 2 Radiopharmaceuticals
A Phase 2 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 2
- Development phase
- 53
- Enrollment target
NCT03125629: Completed Phase 2 study, sponsored by Stanford University.
NCT03125629 is a Phase 2 study that has completed, run by Stanford University. The registered enrollment target is 53 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03125629, a Phase 2 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 53 participants
- Enrollment target
Study Summary
This clinical trial studies how well positron emission tomography (PET)/computed tomography (CT) works compared to PET/magnetic resonance imaging (MRI) in evaluating patients with cancer. PET/CT and PET/MRI may determine which scanner is best for the patient's type of cancer and other types of cancers.
Interventions
- DRUG F-18 FDG
- DRUG Ga-68-DOTA-TATE
- DEVICE Positron Emission Tomography / Computed Tomography (PET/CT) Scan
- DEVICE Positron Emission Tomography / Magnetic Resonance Imaging (PET/MRI) Scan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2014-05-27 |
| Est. Completion | 2020-02-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03125629
The ClinicalTrials.gov registry entry for NCT03125629 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which F-18 FDG is the first listed.
NCT03125629 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03125629 about?
NCT03125629 is a clinical study titled "Comparison of PET/CT vs. PET/MRI Using 2 Radiopharmaceuticals". This clinical trial studies how well positron emission tomography (PET)/computed tomography (CT) works compared to PET/magnetic resonance imaging (MRI) in evaluating patients with cancer. PET/CT and PET/MRI may determine which scanner is best for the patient's type of cancer and other types of cance...
What is the current status of trial NCT03125629?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 53 participants. The study started on 2014-05-27. Estimated completion is 2020-02-05.
What interventions are being tested in trial NCT03125629?
The interventions under investigation include: F-18 FDG (DRUG), Ga-68-DOTA-TATE (DRUG), Positron Emission Tomography / Computed Tomography (PET/CT) Scan (DEVICE), Positron Emission Tomography / Magnetic Resonance Imaging (PET/MRI) Scan (DEVICE).
Who is sponsoring clinical trial NCT03125629?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.